Study: Metformin During Acute COVID Shows Mixed Results for Preventing Long COVID
By
Edited by Archita Rai
Summary
A study led by Carolyn T. Bramante at the University of Minnesota found that a 14-day course of metformin during acute COVID-19 did not definitively prevent long-term symptoms at 6 months. However, relatively fewer clinician-diagnosed long COVID cases were observed, and no major safety signals were detected. The low event rate made evaluation challenging, but the proportion of participants reporting new long COVID diagnoses was encouragingly low.
Source
Key quotes
· 1 pulledWhile a low event rate makes it challenging to evaluate therapeutics, it is encouraging that the proportion of participants reporting new clinician diagnosis of long COVID at 6 months was low.
You might also wanna read
Steroids during acute COVID-19 do not prevent long COVID in children, large RECOVER study finds
This study from the RECOVER Initiative evaluated whether steroid use (dexamethasone, prednisone, prednisolone, methylprednisolone) during ac
Long COVID risk factors identified in large cohort study of 65,000+ U.S. adults
This retrospective cohort study analyzed data from 65,464 U.S. adults in the All of Us Research Program to examine long COVID risk factors.
Study Finds Children with MIS-C Face Significantly Higher Long-Term Health Risks Years After COVID-19
A study of 173 children with MIS-C (multisystem inflammatory syndrome in children) compared to 14,190 without MIS-C, tracked up to 4.5 years
Microfluidic Assay Quantifies Fibrinaloid Clots in Pediatric Long COVID Patients
This research article presents a study using microfluidic assays to quantify fibrinaloid clots in plasma from pediatric Long COVID patients.

Long COVID leads to significant workforce exit and work productivity loss, Dutch cohort study finds
This prospective cohort study (PRIME post-COVID) in the Netherlands assessed workforce exit and work productivity loss among adults with pos

Study Examines Association Between mRNA COVID-19 Vaccination and 4-Year All-Cause Mortality in French Adults Aged 18-59
This cohort study analyzes data from over 28 million French adults aged 18-59 to examine the association between mRNA COVID-19 vaccination a

Comments
Sign in to join the conversation.
No comments yet. Be the first.